{"id":"https://openalex.org/W4231622124","doi":"https://doi.org/10.1182/blood-2020-134609","title":"Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)","display_name":"Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W4231622124","doi":"https://doi.org/10.1182/blood-2020-134609"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-134609","doi":"https://doi.org/10.1182/blood-2020-134609","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-134609","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091882595","display_name":"Pier Luigi Zinzani","orcid":"https://orcid.org/0000-0002-2112-2651","observed_orcids":["https://orcid.org/0000-0002-2112-2651"]},"institutions":[{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Pier Luigi Zinzani","raw_affiliation_strings":["Institute of Hematology \"Ser\u00e0gnoli\" University of Bologna, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Hematology \"Ser\u00e0gnoli\" University of Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I9360294"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088580473","display_name":"Vincent Delwail","orcid":"https://orcid.org/0000-0003-0680-1418","observed_orcids":["https://orcid.org/0000-0003-0680-1418"]},"institutions":[{"id":"https://openalex.org/I4210111187","display_name":"Centre Hospitalier Universitaire de Poitiers","ror":"https://ror.org/029s6hd13","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210111187"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vincent Delwail","raw_affiliation_strings":["CHU Poitiers, Poitiers, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHU Poitiers, Poitiers, France","institution_ids":["https://openalex.org/I4210111187"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066232993","display_name":"Shankara Paneesha","orcid":"https://orcid.org/0000-0002-7446-011X","observed_orcids":["https://orcid.org/0000-0002-7446-011X"]},"institutions":[{"id":"https://openalex.org/I4210104666","display_name":"Heartlands Hospital","ror":"https://ror.org/01bd5gh54","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210104666"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Shankara Paneesha","raw_affiliation_strings":["Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, United Kingdom","institution_ids":["https://openalex.org/I4210104666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059022907","display_name":"Simon A. Rule","orcid":"https://orcid.org/0000-0001-8937-6351","observed_orcids":["https://orcid.org/0000-0001-8937-6351"]},"institutions":[{"id":"https://openalex.org/I4210166818","display_name":"University Hospitals Plymouth NHS Trust","ror":"https://ror.org/05x3jck08","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210166818"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Simon Rule","raw_affiliation_strings":["Plymouth University Hospitals NHS Trust, Plymouth, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Plymouth University Hospitals NHS Trust, Plymouth, United Kingdom","institution_ids":["https://openalex.org/I4210166818"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041947496","display_name":"Alejandro Mart\u0131\u0301n","orcid":"https://orcid.org/0000-0001-6330-1028","observed_orcids":["https://orcid.org/0000-0001-6330-1028","https://orcid.org/0009-0001-9445-8834"]},"institutions":[{"id":"https://openalex.org/I4210134045","display_name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca","ror":"https://ror.org/03em6xj44","country_code":"ES","type":"facility","lineage":["https://openalex.org/I184999862","https://openalex.org/I4210099034","https://openalex.org/I4210134045"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Alejandro Martin Garcia-Sancho","raw_affiliation_strings":["Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain","institution_ids":["https://openalex.org/I4210134045"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002365711","display_name":"Ana Mar\u00edn\u2010Niebla","orcid":"https://orcid.org/0000-0002-7592-6815","observed_orcids":["https://orcid.org/0000-0002-7592-6815"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Ana Marin-Niebla","raw_affiliation_strings":["Hospital Universitari Vall d'Hebron, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitari Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086354986","display_name":"Gilles A. Salles","orcid":"https://orcid.org/0000-0002-9541-8666","observed_orcids":["https://orcid.org/0000-0002-9541-8666"]},"institutions":[{"id":"https://openalex.org/I4210100596","display_name":"Hospices Civils de Lyon","ror":"https://ror.org/01502ca60","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210100596"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Gilles Salles","raw_affiliation_strings":["University Hospital of Lyon, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital of Lyon, Lyon, France","institution_ids":["https://openalex.org/I4210100596"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083191976","display_name":"Juan\u2010Manuel Sancho","orcid":"https://orcid.org/0000-0001-7168-6538","observed_orcids":["https://orcid.org/0000-0001-7168-6538"]},"institutions":[{"id":"https://openalex.org/I4210153460","display_name":"Hospital Universitari Germans Trias i Pujol","ror":"https://ror.org/04wxdxa47","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210153292","https://openalex.org/I4210153460"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Juan-Manuel Sancho","raw_affiliation_strings":["ICO-Hospital Germans Trias i Pujol, Badalona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICO-Hospital Germans Trias i Pujol, Badalona, Spain","institution_ids":["https://openalex.org/I4210153460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104292666","display_name":"Vibeke Vergote","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Vibeke Vergote","raw_affiliation_strings":["University Hospitals Leuven, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospitals Leuven, Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031900135","display_name":"Vittorio Ruggero Zilioli","orcid":"https://orcid.org/0000-0001-6915-2246","observed_orcids":["https://orcid.org/0000-0001-6915-2246"]},"institutions":[{"id":"https://openalex.org/I4210094195","display_name":"Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda","ror":"https://ror.org/00htrxv69","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210094195"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Vittorio Ruggero Zilioli","raw_affiliation_strings":["ASST Grande, Ospedale Metropolitano Niguarda, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ASST Grande, Ospedale Metropolitano Niguarda, Milan, Italy","institution_ids":["https://openalex.org/I4210094195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040883292","display_name":"Fred Zheng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fred Zheng","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071446481","display_name":"Douglas James DeMarini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas J DeMarini","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056623428","display_name":"Wei Jiang","orcid":"https://orcid.org/0000-0002-9079-0792","observed_orcids":["https://orcid.org/0000-0002-9079-0792","https://orcid.org/0009-0005-9656-9262"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei Jiang","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030631799","display_name":"Amitkumar Mehta","orcid":"https://orcid.org/0000-0003-0537-4207","observed_orcids":["https://orcid.org/0000-0003-0537-4207"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amitkumar Mehta","raw_affiliation_strings":["UAB School of Medicine, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UAB School of Medicine, Birmingham, AL","institution_ids":["https://openalex.org/I32389192","https://openalex.org/I4390039250"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":2.2091,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.89490362,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"43","last_page":"44"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9449999928474426},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.8999999761581421},{"id":"https://openalex.org/keywords/parsaclisib","display_name":"parsaclisib","score":0.9729999899864197},{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.9200000166893005},{"id":"https://openalex.org/keywords/ibrutinib-resistance","display_name":"ibrutinib resistance","score":0.9509999752044678},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.9160000085830688},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.3889999985694885},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.6610000133514404},{"id":"https://openalex.org/keywords/pneumocystis-pneumonia-prophylaxis","display_name":"Pneumocystis carinii pneumonia prophylaxis","score":0.8330000042915344},{"id":"https://openalex.org/keywords/once-weekly-dosing","display_name":"weekly dosing","score":0.46299999952316284},{"id":"https://openalex.org/keywords/daily-dosing","display_name":"daily dosing","score":0.7760000228881836},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6269999742507935}],"concepts":[{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.8945406675338745},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7677174210548401},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.7659076452255249},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6721706986427307},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6584576368331909},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5202411413192749},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4551423192024231},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.45035654306411743},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.44120484590530396},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.41110485792160034},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3258822560310364},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.3163783550262451},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.23200908303260803},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.20244842767715454},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.17368629574775696},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.15955278277397156}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-134609","doi":"https://doi.org/10.1182/blood-2020-134609","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-134609","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3096345204","https://openalex.org/W3217796278","https://openalex.org/W4385738741","https://openalex.org/W4389979814","https://openalex.org/W3097179004","https://openalex.org/W3212937025","https://openalex.org/W4283382358","https://openalex.org/W4212905895","https://openalex.org/W2959327776","https://openalex.org/W4310119385"],"abstract_inverted_index":{"Background:":[0],"Mantle":[1],"cell":[2,326],"lymphoma":[3],"(MCL)":[4],"accounts":[5],"for":[6,22,76,164,185,344,358,370,423,438],"approximately":[7],"5-7%":[8],"of":[9,24,82,107,205,257,283,313,320,453,484,508,583,589,655,669,684,703,718,732,751,766,781,796,810,824,840,854,869,883,897,912,926,941,961,1133,1150,1192],"non-Hodgkin":[10],"lymphomas":[11],"(NHL).":[12],"Bruton's":[13],"tyrosine":[14],"kinase":[15],"(BTK)":[16],"inhibitors,":[17],"eg":[18],"ibrutinib,":[19],"are":[20],"indicated":[21],"treatment":[23,148,514,571],"adults":[25],"with":[26,44,66,84,91,109,149,626],"MCL":[27,86,306],"who":[28,87],"have":[29,127],"received":[30,138],"\u22651":[31],"prior":[32,142,314,323],"therapy.":[33,336],"Primary":[34],"and":[35,42,47,137,214,216,281,302,328,350,366,377,382,389,392,419,434,463,472,492,506,522,535,551,565,572,597,633],"acquired":[36],"resistance":[37],"to":[38,115,140,156,233,265,332,399,498,513,558,570],"ibrutinib":[39,92],"is":[40,252,617],"common":[41,445,477],"linked":[43],"poor":[45],"outcomes,":[46],"remains":[48],"an":[49,629,652,666,681,700,715,729,748,763,778,793,807,821,837,851,866,880,894,909,923,938,958,1130,1147,1189],"unmet":[50],"medical":[51],"need.":[52],"Parsaclisib,":[53],"a":[54,80],"potent,":[55],"highly-selective,":[56],"next-generation":[57],"PI3K\u03b4":[58],"inhibitor,":[59],"demonstrated":[60],"clinical":[61,584],"activity":[62],"in":[63,79,93,348,352,385,395,451,482,504,517,527,587,606,620,1102,1112,1122],"patients":[64],"(pts)":[65],"relapsed":[67],"or":[68,124,177,401,501,576,657,671,686,705,720,734,753,768,783,798,812,826,842,856,871,885,899,914,928,943,963,1135,1152,1194],"refractory":[69,331],"(R/R)":[70],"NHL.":[71],"We":[72],"report":[73],"preliminary":[74],"results":[75,640],"parsaclisib":[77,158,615,627],"monotherapy":[78,616],"cohort":[81],"pts":[83,240,258,284,296,321,341,454,485,520,529,540,590],"R/R":[85,113],"were":[88,154,218,224,241,285,330,342,379,455,530,601],"previously":[89],"treated":[90,242],"the":[94,116,197],"open-label,":[95],"phase":[96],"2":[97,518],"study":[98,639],"CITADEL-205":[99],"(NCT03235544).":[100],"Methods:":[101],"Pts":[102,153],"must":[103],"be":[104,642],"\u226518":[105],"years":[106,280],"age":[108,277],"pathologically":[110],"confirmed":[111],"MCL,":[112],"disease":[114,267,573],"most":[117,262,333,444],"recent":[118,334],"treatment,":[119,261],"documented":[120],"cyclin":[121],"D1":[122],"overexpression":[123],"t(11;14)":[125],"translocation,":[126],"Eastern":[128],"Cooperative":[129],"Oncology":[130],"Group":[131],"performance":[132],"status":[133],"(ECOG":[134],"PS)":[135],"\u22642,":[136],"1":[139],"3":[141],"systemic":[143,315,335],"treatments":[144],"(including":[145],"ibrutinib).":[146],"Prior":[147],"PI3Ki":[150],"was":[151,190,196,272,278,292,317,361,404,411,429,634],"prohibited.":[152],"allocated":[155],"receive":[157],"20":[159,170],"mg":[160,171,179],"once":[161,172],"daily":[162],"(QD)":[163],"8":[165],"weeks":[166],"followed":[167],"by":[168],"either":[169],"weekly":[173],"(weekly-dosing":[174],"group":[175,182],"[WG])":[176],"2.5":[178],"QD":[180],"(daily-dosing":[181],"[DG]).":[183],"Prophylaxis":[184],"Pneumocystis":[186],"jirovecii":[187],"pneumonia":[188,536],"(PJP)":[189],"required.":[191],"Objective":[192],"response":[193,201,206,403],"rate":[194,202],"(ORR)":[195],"primary":[198],"endpoint;":[199],"complete":[200,400],"(CRR),":[203],"duration":[204],"(DOR),":[207],"progression-free":[208],"survival":[209,212],"(PFS),":[210],"overall":[211,365,433],"(OS),":[213],"safety":[215,631],"tolerability":[217],"secondary":[219],"endpoints.":[220],"All":[221],"radiology-based":[222],"endpoints":[223],"based":[225],"on":[226,651,665,680,699,714,728,747,762,777,792,806,820,836,850,865,879,893,908,922,937,957,1129,1146,1188],"independent":[227],"review.":[228],"Results:":[229],"From":[230],"October":[231],"2017":[232],"January":[234],"17,":[235],"2020":[236],"(data":[237],"cut-off),":[238],"47":[239,441],"(WG,":[243],"n":[244,248],"=":[245,249],"12;":[246],"DG,":[247],"35).":[250],"Enrollment":[251],"ongoing.":[253],"At":[254,337],"cut-off,":[255,339],"70%":[256],"had":[259,298,304,322,546,562,628],"discontinued":[260],"commonly":[263],"due":[264],"progressive":[266],"(62%).":[268],"Median":[269,276,287,355,397,407,425],"exposure":[270],"(range)":[271,357],"2.2":[273],"(0.1-18.0)":[274],"months.":[275],"70":[279],"79%":[282],"men.":[286],"time":[288,398],"since":[289],"initial":[290],"diagnosis":[291],"4.7":[293],"years.":[294],"Most":[295,476],"(85%)":[297],"ECOG":[299],"PS":[300],"\u22641":[301],"51%":[303],"high-risk":[305],"International":[307],"Prognostic":[308],"Index.":[309],"The":[310],"median":[311],"number":[312],"therapies":[316],"3;":[318],"38%":[319,329],"hematopoietic":[324],"stem":[325],"transplant,":[327],"data":[338,612],"46":[340],"evaluable":[343,387],"efficacy,":[345],"including":[346],"12":[347],"WG":[349],"34":[351],"DG":[353],"(Table).":[354],"follow-up":[356],"this":[359,621],"population":[360],"10.2":[362],"months":[363,368,413,421,431,436],"(1.5-25.9)":[364,369],"7.6":[367,405],"DG.":[371,396,424,439],"ORR":[372],"(95%":[373,409,427],"confidence":[374],"interval":[375],"[CI])":[376],"CRR":[378],"28.3%":[380],"(16.0-43.5)":[381],"2.2%,":[383],"respectively":[384,394],"all":[386,417],"pts,":[388,443,509],"35.3%":[390],"(19.7-53.5)":[391],"2.9%,":[393],"partial":[402],"weeks.":[406],"DOR":[408],"CI)":[410,428],"7.3":[412],"(0.2-not":[414],"estimable)":[415],"among":[416],"responders":[418],"3.7":[420],"(0.2-7.3)":[422],"PFS":[426],"3.65":[430,435],"(1.9-3.9)":[432],"(1.9-5.5)":[437],"Among":[440],"safety-evaluable":[442],"treatment-emergent":[446],"adverse":[447],"events":[448],"(TEAEs)":[449],"occurring":[450,586],">10%":[452],"anemia":[456,487],"(19.1%),":[457,459],"diarrhea":[458],"neutropenia":[460,489],"(14.9%),":[461,594],"asthenia":[462],"cough":[464],"(12.8%":[465],"each),":[466],"decreased":[467,592],"appetite,":[468],"dyspnea,":[469,532],"fatigue,":[470],"pyrexia":[471],"rash":[473,493],"(10.6%":[474],"each).":[475,495,538],"grade":[478,578,603],"\u22653":[479,579,604],"TEAEs":[480,496,511,525,543],"reported":[481,526],"\u22655%":[483,588],"included":[486,591],"(12.8%),":[488],"(10.6%),":[490,596],"thrombocytopenia":[491],"(6.4%":[494],"leading":[497,512],"dose":[499],"interruption":[500],"reduction":[502],"occurred":[503,516],"31.9%":[505],"2.1%":[507],"respectively.":[510],"discontinuation":[515],"(4.3%)":[519],"(diarrhea":[521],"colitis).":[523],"Serious":[524],"\u22652":[528],"diarrhea,":[531],"peripheral":[533],"swelling":[534],"(4.3%":[537],"Two":[539],"experienced":[541],"fatal":[542],"(one":[544],"pt":[545,561],"general":[547],"physical":[548],"health":[549],"deterioration":[550],"respiratory":[552],"tract":[553],"infection,":[554],"deemed":[555,568],"not":[556],"related":[557,569],"treatment;":[559],"one":[560],"pneumonia,":[563],"neutropenia,":[564],"septic":[566],"shock,":[567],"progression).":[574],"New":[575],"worsening":[577],"laboratory":[580],"test":[581],"values":[582],"interest":[585],"neutrophils":[593],"platelets":[595],"hemoglobin":[598],"(8.5%);":[599],"there":[600],"no":[602],"increases":[605],"alanine/aspartate":[607],"aminotransferase.":[608],"Conclusion:":[609],"Preliminary":[610],"efficacy":[611],"indicate":[613],"that":[614],"clinically":[618],"active":[619],"difficult-to-treat":[622],"patient":[623],"population.":[624],"Treatment":[625],"acceptable":[630],"profile":[632],"generally":[635],"well":[636],"tolerated.":[637],"Updated":[638],"will":[641],"presented.":[643],"Disclosures":[644],"Zinzani:":[645],"EUSA":[646],"Pharma:":[647,1054,1057],"Consultancy,":[648,677,693,740,745,759,774,789,818,834,848,862,877,906,920,955,967,991,999,1023,1026,1032,1037,1040,1043,1051,1060,1074,1079,1082,1085,1088,1091,1127,1144,1186],"Honoraria,":[649,663,678,697,712,741,760,775,790,804,863,891,935,951,1027,1033,1044],"Membership":[650,664,679,698,713,727,746,761,776,791,805,819,835,849,864,878,892,907,921,936,956,1128,1145,1187],"entity's":[653,667,682,701,716,730,749,764,779,794,808,822,838,852,867,881,895,910,924,939,959,1131,1148,1190],"Board":[654,668,683,702,717,731,750,765,780,795,809,823,839,853,868,882,896,911,925,940,960,1132,1149,1191],"Directors":[656,670,685,704,719,733,752,767,782,797,811,825,841,855,870,884,898,913,927,942,962,1134,1151,1193],"advisory":[658,672,687,706,721,735,754,769,784,799,813,827,843,857,872,886,900,915,929,944,964,1136,1153,1195],"committees,":[659,673,688,707,722,736,755,770,785,800,814,828,844,858,873,887,901,916,930,945,1137,1154,1196],"Speakers":[660,674,689,694,708,723,737,742,756,771,786,801,815,831,845,859,874,888,902,917,931,946,952,968,994,1140,1157,1199],"Bureau;":[661,675,690,695,709,724,738,743,757,772,787,802,816,832,846,860,875,889,903,918,932,947,953,995,1141,1158,1200],"AbbVie:":[662,981],"Gilead:":[676,977,1007,1087],"Kyowa":[691,1014],"Kirin:":[692],"Takeda:":[696,1076,1205],"ADC":[710],"Therapeutics:":[711,1143],"Immune":[725,904],"Design:":[726,905],"Janssen:":[739,979,1036,1084],"Sandoz:":[744],"Roche:":[758,1073],"BMS:":[773],"Servier:":[788,1050],"Merck:":[803,1059,1165],"Portola:":[817],"Research":[829,992,1000,1028,1034,1048,1061,1138,1155,1160,1163,1166,1169,1173,1177,1180,1183,1197,1203,1206],"Funding,":[830,993,1139,1156,1198],"Celltrion:":[833,987,1071],"MSD:":[847],"Verastem:":[861],"Celgene:":[876,975,985,1025,1090],"Incyte:":[890,1185],"Janssen-Cilag:":[919],"Kirin":[933],"Kyowa:":[934],"TG":[948,1142],"Therapeutics,":[949],"Inc.:":[950],"Sanofi:":[954,1067],"committees;":[965],"Eusapharma:":[966],"Bureau.":[969],"Delwail:Amgen:":[970],"Consultancy.":[971,1018],"Paneesha:Bristol-Myers":[972],"Squibb:":[973,1022,1094],"Honoraria;":[974,976,978,980,1008,1020,1024,1038,1041,1052,1075,1077,1080,1083,1086,1089,1092],"Honoraria.":[982,1095],"Rule:AstraZeneca:":[983],"Consultancy;":[984,986,988,1055,1058,1064,1066,1070,1072],"Janssen":[989],"Oncology:":[990],"Roche":[996],"Pharma":[997],"AG:":[998],"Funding.":[1001,1207],"Martin":[1002],"Garcia-Sancho:Roche,":[1003],"Celgene,":[1004,1009],"Janssen,":[1005],"Servier,":[1006],"Eusa":[1010],"Pharma,":[1011],"Gilead,":[1012],"iQuone,":[1013],"Kirin,":[1015],"Roche,":[1016],"Morphosys:":[1017],"Salles:Amgen:":[1019],"Bristol-Myers":[1021,1093],"Funding;":[1029,1035,1049,1062,1161,1164,1167,1170,1174,1178,1181,1184,1204],"Gilead":[1030],"Sciences:":[1031],"Novartis:":[1039,1078],"Roche/Genentech:":[1042],"Other:":[1045],"Travel":[1046],"expenses,":[1047],"Acerta":[1053],"Kite":[1056],"Novimmune:":[1063],"Pfizer:":[1065],"Other.":[1068],"Sancho:Sandoz:":[1069],"Kern-Pharma:":[1081],"Zheng:Incyte:":[1096],"Current":[1097,1099,1107,1109,1117,1119],"Employment,":[1098,1108,1118],"equity":[1100,1110,1120],"holder":[1101,1111,1121],"publicly-traded":[1103,1113,1123],"company.":[1104,1114,1124],"DeMarini:Incyte":[1105],"Corporation:":[1106,1116],"Jiang:Incyte":[1115],"Mehta:Seattle":[1125],"Genetics:":[1126],"Gelgene/BMS:":[1159],"Affimed:":[1162],"Kite/Gilead:":[1168],"Juno":[1171],"Parmaceuticals/BMS:":[1172],"Innate":[1175],"Pharmaceuticals:":[1176],"Oncotartis:":[1179],"Roche-Genentech:":[1182],"fortyseven":[1201],"Inc/Gilead:":[1202]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2022-05-12T00:00:00"}